Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026)

Amarin Corp Plcuk (AMRN) reported Total Non-Current Liabilities of $185.2 million for Q1 2026, up 8.74% year-over-year from $170.3 million in Q1 2025, and down 7.63% quarter-over-quarter from $200.5 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk (AMRN) has 17 years of Total Non-Current Liabilities data on file, last reported at $185.2 million in Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $185.2 million, up 8.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $185.2 million (up 8.74% YoY), and the FY2025 annual result was $200.5 million, up 6.86% from the prior year.
  • Total Non-Current Liabilities slipped to $185.2 million in Q1 2026 per AMRN's latest filing, from $200.5 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $385.6 million in Q2 2022 and troughed at $170.3 million in Q1 2025.
  • A 5-year average of $247.8 million and a median of $238.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities plunged 30.63% in 2024, then gained 8.74% in 2026.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $282.6 million in 2022, then retreated by 4.29% to $270.5 million in 2023, then sank by 30.63% to $187.7 million in 2024, then climbed by 6.86% to $200.5 million in 2025, then dropped by 7.63% to $185.2 million in 2026.
  • Business Quant data shows AMRN's Total Non-Current Liabilities at $185.2 million in Q1 2026, $200.5 million in Q4 2025, and $189.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -31.03 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 48.74 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 119.22 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 108.96 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 75.11 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 31.56 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 113.51 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 61.52 Bn
10 Amarin Corp Plcuk 5.84 Bn 5.66 Bn 17.77 Mn 185.23 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 185.23 Mn
Dec 31, 2025 200.54 Mn
Sep 30, 2025 188.96 Mn
Jun 30, 2025 193.28 Mn
Mar 31, 2025 170.35 Mn
Dec 31, 2024 187.67 Mn
Sep 30, 2024 209.77 Mn
Jun 30, 2024 238.64 Mn
Mar 31, 2024 234.88 Mn
Dec 31, 2023 270.52 Mn
Sep 30, 2023 278.61 Mn
Jun 30, 2023 283.74 Mn
Mar 31, 2023 266.79 Mn
Dec 31, 2022 282.64 Mn
Sep 30, 2022 310.78 Mn
Jun 30, 2022 385.56 Mn
Mar 31, 2022 325.11 Mn
Dec 31, 2021 393.32 Mn
Sep 30, 2021 387.96 Mn
Jun 30, 2021 394.14 Mn